Pfizer (PFE) Tops Q1 EPS by 29c, Beats on Revenue; Offers FY24 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Pfizer stock climbs as first quarter earnings, revenue come ahead of estimates
May 1, 2024 6:53 AM EDTPfizer (NYSE: PFE) shares rose 3% in premarket trading Wednesday after the drugmaker reported Q1 earnings and revenue that beat analyst estimates.
Earnings per share (EPS) stood at $0.82, exceeding the consensus estimates of $0.53. Revenue came in at $14.9 billion, also above the consensus projection of $14.04 billion.
Meanwhile, adjusted research and development (R&D) expenses... More
